Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.37 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772837 | 0.84 | CKS1B (0.47) | — | |
| SCHEMBL23301263 | 0.82 | KCNH2 (0.43) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23037212 | 0.81 | MEN1 (0.60) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23303000 | 0.80 | CHRM4 (0.36) | SMARCA2SMARCA4PBRM1CHRM4 | |
| SCHEMBL31179821 | 0.79 | PBRM1 (0.57) | SMARCA2SMARCA4PBRM1LMNAHTT | |
| SCHEMBL23037243 | 0.79 | PBRM1 (0.57) | SMARCA2SMARCA4PBRM1LMNAHTT | |
| SCHEMBL23037258 | 0.77 | PBRM1 (0.69) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL23037203 | 0.76 | PBRM1 (0.38) | SMARCA2SMARCA4PBRM1LMNAHTT | |
| SCHEMBL23037167 | 0.75 | LMNA (0.40) | SMARCA2SMARCA4PBRM1LMNAMEN1 | |
| SCHEMBL2002846 | 0.74 | LMNA (0.68) | LMNAHTTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | SMARCA2 3/4885SMARCA4 5/4885PBRM1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.